{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:20:32Z","timestamp":1783059632526,"version":"3.54.6"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.annder.2025.103377","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T09:57:24Z","timestamp":1746266244000},"page":"103377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Apremilast: Real-life efficacy and safety in psoriasis limited to the nails"],"prefix":"10.1016","volume":"152","author":[{"given":"M.","family":"Iorizzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.R.","family":"Lipner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pacifico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rigopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Villani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Zaraa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Richert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2025.103377_b0005","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1185\/030079908X301866","article-title":"An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast","volume":"24","author":"Gottlieb","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.annder.2025.103377_b0010","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","article-title":"Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis","volume":"159","author":"Schafer","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.annder.2025.103377_b0015","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0140-6736(12)60642-4","article-title":"Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial","volume":"380","author":"Papp","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2025.103377_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000316169","article-title":"The burden of nail psoriasis: an introduction","volume":"221S1","author":"Baran","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.annder.2025.103377_b0025","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/jdv.12368","article-title":"Nail Psoriasis, the unknown burden of disease","volume":"28","author":"Klaassen","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2025.103377_b0030","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.jaad.2022.12.031","article-title":"The untold burden of isolated nail psoriasis: delayed diagnosis and significant risk of psoriatic arthritis in a retrospective study at an academic center","volume":"88","author":"Chang","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2025.103377_b0035","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000512688","article-title":"The impact of nail psoriasis and treatment on quality of life: a systematic review","volume":"7","author":"Stewart","year":"2021","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.annder.2025.103377_b0040","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/art.24172","article-title":"Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study","volume":"61","author":"Wilson","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.annder.2025.103377_b0045","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaad.2015.09.001","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)","volume":"74","author":"Rich","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2025.103377_b0050","first-page":"221","article-title":"Efficacy and safety of apremilast in systemic-and biologic-naive patients with moderate plaque psoriasis: 52-week results of UNVEIL","volume":"17","author":"Gold","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.annder.2025.103377_b0055","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/jdv.14738","article-title":"Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study","volume":"32","author":"Reich","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2025.103377_b0060","doi-asserted-by":"crossref","first-page":"AB438","DOI":"10.1016\/j.jaad.2019.10.105","article-title":"Real-world experience with apremilast: analysis of 250 patients from the APPRECIATE study with psoriasis in difficult-to-treat areas","volume":"81","author":"Radtke","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2025.103377_b0065","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/jdv.16431","article-title":"Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study","volume":"35","author":"Augustin","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2025.103377_b0070","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/jdv.18689","article-title":"Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: results from the EMBRACE randomized trial","volume":"37","author":"Mrowietz","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2025.103377_b0075","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1046\/j.1365-2133.1998.02031.x","article-title":"A simplified protocol of steroid injection for psoriatic nail dystrophy","volume":"138","author":"de Berker","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2025.103377_b0080","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/ced.15110","article-title":"A pilot study of intralesional methotrexate injections versus triamcinolone acetonide in patients affected by nail matrix psoriasis","volume":"47","author":"Starace","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.annder.2025.103377_b0085","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jaad.2019.01.072","article-title":"Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus","volume":"81","author":"Rigopoulos","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2025.103377_b0090","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.jaad.2020.05.087","article-title":"Improvement of 11 patients with nail psoriasis with apremilast: results of an investigator-initiated open-label study","volume":"83","author":"Oak","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2025.103377_b0095","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/1346-8138.16074","article-title":"Apremilast improves quality of life and ultrasonography parameters in patients with nail psoriasis: a prospective cohort study","volume":"48","author":"Mu\u00f1oz-Santos","year":"2021","journal-title":"J Dermatol"},{"key":"10.1016\/j.annder.2025.103377_b0100","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/09546634.2020.1801976","article-title":"Apremilast as a target therapy for nail psoriasis: a real-life observational study proving its efficacy in restoring the nail unit","volume":"33","author":"Lanna","year":"2022","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.annder.2025.103377_b0105","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2025.103377_b0110","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13075-019-1901-3","article-title":"Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1\u20133 pooled analysis","volume":"21","author":"Kavanaugh","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.annder.2025.103377_b0115","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjd.12670","article-title":"Psoriasis and smoking: a systematic review and meta-analysis","volume":"170","author":"Armstrong","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2025.103377_b0120","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1093\/rheumatology\/keaa179","article-title":"The impact of smoking on prevalence of psoriasis and psoriatic arthritis","volume":"59","author":"Gazel","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.annder.2025.103377_b0125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/1358863X221126205","article-title":"Association of electronic cigarette use with circulating angiogenic cell levels in healthy young adults: evidence for chronic systemic injury","volume":"28","author":"Amraotkar","year":"2023","journal-title":"Vasc Med"},{"key":"10.1016\/j.annder.2025.103377_b0130","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2340\/00015555-3221","article-title":"Smoking does not alter the therapy response to systemic anti-psoriatic therapies: a two-country, multi-centre, prospective, non-interventional study","volume":"99","author":"Anzengruber","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.annder.2025.103377_b0135","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1111\/jdv.18611","article-title":"No Association of Metabolic Syndrome with isolated nail psoriasis in a retrospective single-centre academic study","volume":"37","author":"Miller","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963825000365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963825000365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T23:36:36Z","timestamp":1748648196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963825000365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0151963825000365"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2025.103377","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apremilast: Real-life efficacy and safety in psoriasis limited to the nails","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2025.103377","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103377"}}